neomycin
Sign in to saveKey facts
- Drug.IUPAC_name
- (2RS,3S,4S,5R)-5-Amino-2-(aminomethyl)-6-((2R,3S,4R,5S)-5-((1R,2R,5R,6R)-3,5-diamino-2-((2R,3S,4R,5S)-3-amino-6-(aminomethyl)-4,5-dihydroxytetrahydro-2H-pyran-2-yloxy)-6-hydroxycyclohexyloxy)-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yloxy)tetrahydro-2H-pyran-3,4-diol
- Drug.image
- Neomycin B C.svg
- Drug.image_class
- skin-invert-image
- Drug.image2
- Neomycin ball-and-stick.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Neo-rx
- Drug.MedlinePlus
- a682274
- Drug.pregnancy_US
- D
- Drug.legal_US
- Rx-only
- Drug.legal_US_comment
- but OTC in Neosporin and similar ointments
- Drug.routes_of_administration
- Topical, oral
- Drug.bioavailability
- None
- Drug.protein_bound
- N/A
- Drug.metabolism
- N/A
- Drug.elimination_half life
- 2 to 3 hours
- Drug.CAS_number
- 1404-04-2
- Drug.ATC_prefix
- A01
- Drug.ATC_suffix
- AB08
via Wikipedia infobox
Article
11 sectionsContents
- Discovery
- Medical uses
- Spectrum
- Side effects
- Molecular biology
- Activity
- Resistance
- Biosynthetic pathway
- Composition
- DNA binding
- References
Neomycin, also known as framycetin, is an aminoglycoside antibiotic that displays bactericidal activity against Gram-negative aerobic bacilli and some anaerobic bacilli where resistance has not yet arisen. It is generally not effective against Gram-positive bacilli and anaerobic Gram-negative bacilli. Neomycin comes in oral and topical formulations, including creams, ointments, and eyedrops. Neomycin belongs to the aminoglycoside class of antibiotics that contain two or more amino sugars connected by glycosidic bonds.
Neomycin was discovered in 1949 by microbiologist Selman Waksman and his student Hubert Lechevalier at Rutgers University. Neomycin received approval for medical use in 1952. Rutgers University was granted the patent for neomycin in 1957.